Vanguard Group’s RVL Pharmaceuticals RVLP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-246,353
Closed -$21.3K – 4578
2023
Q3
$21.3K Hold
246,353
– – ﹤0.01% 4492
2023
Q2
$138K Hold
246,353
– – ﹤0.01% 4363
2023
Q1
$281K Hold
246,353
– – ﹤0.01% 4266
2022
Q4
$276K Buy
246,353
+23,918
+11% +$38.1K ﹤0.01% 4242
2022
Q3
$467K Hold
222,435
– – ﹤0.01% 4231
2022
Q2
$302K Buy
222,435
+14,493
+7% +$21K ﹤0.01% 4407
2022
Q1
$352K Hold
207,942
– – ﹤0.01% 4447
2021
Q4
$225K Sell
207,942
-2,492
-1% -$4.04K ﹤0.01% 4545
2021
Q3
$621K Hold
210,434
– – ﹤0.01% 4346
2021
Q2
$634K Sell
210,434
-57,973
-22% -$177K ﹤0.01% 4232
2021
Q1
$875K Buy
268,407
+7,197
+3% +$29.6K ﹤0.01% 4043
2020
Q4
$1.08M Buy
261,210
+6,786
+3% +$39.1K ﹤0.01% 3810
2020
Q3
$1.38M Buy
254,424
+309
+0.1% +$1.78K ﹤0.01% 3587
2020
Q2
$1.71M Buy
254,115
+27,824
+12% +$136K ﹤0.01% 3473
2020
Q1
$719K Buy
226,291
+120,259
+113% +$640K ﹤0.01% 3584
2019
Q4
$741K Buy
106,032
+664
+0.6% +$3.54K ﹤0.01% 3704
2019
Q3
$405K Sell
105,368
-16,231
-13% -$55K ﹤0.01% 3859
2019
Q2
$462K Sell
121,599
-222
-0.2% -$738 ﹤0.01% 3840
2019
Q1
$438K Buy
121,821
+8,137
+7% +$59.9K ﹤0.01% 3796
2018
Q4
$881K Buy
+113,684
New +$910K ﹤0.01% 3597

Other funds holding RVLP

Vanguard Group's RVLP Position: Q4 2023 in Review

Vanguard Group sold out of RVL Pharmaceuticals (RVLP) in Q4 2023, closing a stake of 246,353 shares — an estimated $21.3K sold.

Vanguard Group first reported a position in RVLP in Q4 2018 and held it in 20 quarters. The position peaked at $1.71M in Q2 2020. 3 funds tracked by Wall St. Rank hold RVLP as of Q4 2023.

  • Vanguard Group reported no remaining RVL Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Vanguard Group sold 246,353 RVL Pharmaceuticals shares in Q4 2023, an estimated $21.3K.
  • Vanguard Group first reported a position in RVL Pharmaceuticals in Q4 2018 and held it in 20 quarters.
  • Vanguard Group's RVL Pharmaceuticals position peaked at $1.71M in Q2 2020.
  • 3 funds tracked by Wall St. Rank held RVL Pharmaceuticals as of Q4 2023.

Based on Vanguard Group's 13F filing for Q4 2023, filed 14 Feb 2024.